...TSX:BHC; NYSE:BHC); Eldepryl selegiline from Orion Corp. (HSE:ORNAV; HSE:ORNBV) and Eisai Co. Ltd. (Tokyo:4523); Azilect rasagiline mesylate...

...a delivery technology such as ATV. The pharma’s only other disclosed PD asset is Azilect rasagiline mesylate...
...Undisclosed Undisclosed Jan. 2016 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) Japanese rights to Azilect rasagiline mesylate...

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an NDA in Japan for Azilect rasagiline mesylate (TVP-1012) to treat...
...Agilect) (TVP-1012) Business: Neurology Julian Zhu Azilect rasagiline TVP-1012 H. Lundbeck A/S Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd. Monoamine oxidase B (MAO-B) rasagiline mesylate...

...for multiple sclerosis drug Copaxone glatiramer acetate, and a 2014 deal for Parkinson's disease drug Azilect...

...far is Copaxone, with $1.1 billion in sales during 2Q15. Sales of Parkinson's disease drug Azilect...

...DKK3.19B ($542.9M) but came in above the Street's DKK3.14B estimate. Sales of Parkinson's disease drug Azilect...

...DKK3.448B ($631M) and were slightly below the Street's DKK3.452B estimate. Sales of Parkinson's disease drug Azilect...

...of PD. Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S and Takeda Pharmaceutical Co. Ltd. market Agilect/Azilect...

...FDA approved an sNDA for Azilect rasagiline to include use as an adjunct to dopamine agonists...
...Israel H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Azilect...

...drug Ebixa memantine to DKK183M ($33.7M) due to generic competition. Sales of Parkinson's disease drug Azilect...